|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Prat J, D'Angelo E and Espinosa I: Ovarian
carcinomas: At least five different diseases with distinct
histological features and molecular genetics. Hum Pathol. 80:11–27.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kurman RJ, Carcangiu ML, Herrington CS and
Young RH: WHO classification of tumors of female reproductive
organs. IARC. 2014.
|
|
4
|
D'Angelo E and Prat J: Pathology of mixed
Mullerian tumours. Best Pract Res Clin Obstet Gynaecol. 25:705–718.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Davidson B: Ovarian and primary peritoneal
carcinoma. Serous Effusions - Etiology, Diagnosis, Prognosis and
Therapy. Davidson B, Firat P and Michael CW: Springer; London, UK:
pp. 47–68, 167-204. 2011
|
|
6
|
Piche A: Malignant peritoneal effusion
acting as a tumor environment in ovarian cancer progression: Impact
and significance. World J Clin Oncol. 9:167–171. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Davidson B: Recently identified drug
resistance biomarkers in ovarian cancer. Expert Rev Mol Diagn.
16:569–578. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Davidson B: Biomarkers of drug resistance
in ovarian cancer-an update. Expert Rev Mol Diagn. 19:469–476.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brunetti M, Holth A, Panagopoulos I, Staff
AC, Micci F and Davidson B: Expression and clinical role of the
dipeptidyl peptidases DPP8 and DPP9 in ovarian carcinoma. Virchows
Archiv. 474:177–185. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Davidson B, Stavnes HT, Holth A, Chen X,
Yang Y, Shih IeM and Wang TL: Gene expression signatures
differentiate ovarian/peritoneal serous carcinoma from breast
carcinoma in effusions. J Cell Mol Med. 15:535–544. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shah RH, Scott SN, Brannon AR, Levine DA,
Lin O and Berger MF: Comprehensive mutation profiling by
next-generation sequencing of effusion fluids from patients with
high-grade serous ovarian carcinoma. Cancer Cytopathol.
123:289–297. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nagel H, Schulten HJ, Gunawan B, Brinck U
and Fuzesi L: The potential value of comparative genomic
hybridization analysis in effusion-and fine needle aspiration
cytology. Mod Pathol. 15:818–825. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Malcikova J, Tausch E, Rossi D, Sutton LA,
Soussi T, Zenz T, Kater AP, Niemann CU, Gonzalez D, Davi F, et al:
ERIC recommendations for TP53 mutation analysis in chronic
lymphocytic leukemia-update on methodological approaches and
results interpretation. Leukemia. 32:1070–1080. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Brunetti M, Agostini A, Staurseth J,
Davidson B, Heim S and Micci F: Molecular characterization of
carcinosarcomas arising in the uterus and ovaries. Oncotarget.
10:3614–3624. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tate JG, Bamford S, Jubb HC, Sondka Z,
Beare DM, Bindal N, Boutselakis H, Cole CG, Creatore C, Dawson E,
et al: COSMIC: The catalogue of somatic mutations in cancer.
Nucleic Acids Res. 47:D941–D947. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Olshen AB, Venkatraman ES, Lucito R and
Wigler M: Circular binary segmentation for the analysis of
array-based DNA copy number data. Biostatistics. 5:557–572. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ried T, Heselmeyer-Haddad K, Blegen H,
Schröck E and Auer G: Genomic changes defining the genesis,
progression, and malignancy potential in solid human tumors: A
phenotype/genotype correlation. Genes Chromosomes Cancer.
25:195–204. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Micci F, Teixeira MR, Haugom L, Kristensen
G, Abeler VM and Heim S: Genomic aberrations in carcinomas of the
uterine corpus. Genes Chromosomes Cancer. 40:229–246. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jackson SE and Chester JD: Personalised
cancer medicine. Int J Cancer. 137:262–266. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang W, Edwards A, Flemington EK and
Zhang K: Significant prognostic features and patterns of somatic
TP53 mutations in human cancers. Cancer Inform.
16:11769351176912672017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
simplewww.sanger.ac.uk/genetics/CGP/cosmic
|
|
22
|
Li H, Zeng J and Shen K: PI3K/AKT/mTOR
signaling pathway as a therapeutic target for ovarian cancer. Arch
Gynecol Obstet. 290:1067–1078. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Samuels Y and Waldman T: Oncogenic
mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol.
347:21–41. 2010.PubMed/NCBI
|
|
24
|
Campbell IG, Russell SE, Choong DY,
Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB and
Phillips WA: Mutation of the PIK3CA gene in ovarian and breast
cancer. Cancer Res. 64:7678–7681. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mabuchi S, Kuroda H, Takahashi R and
Sasano T: The PI3K/AKT/mTOR pathway as a therapeutic target in
ovarian cancer. Gynecol Oncol. 137:173–179. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gasparri ML, Bardhi E, Ruscito I, Papadia
A, Farooqi AA, Marchetti C, Bogani G, Ceccacci I, Mueller MD and
Benedetti Panici P: PI3K/AKT/mTOR pathway in ovarian cancer
treatment: Are we on the right track? Geburtshilfe Frauenheilkd.
77:1095–1103. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fernández-Medarde A and Santos E: Ras in
cancer and developmental diseases. Genes Cancer. 2:344–358. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nodin B, Zendehrokh N, Sundstrom M and
Jirstrom K: Clinicopathological correlates and prognostic
significance of KRAS mutation status in a pooled prospective cohort
of epithelial ovarian cancer. Diagn Pathol. 8:1062013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Dobrzycka B, Terlikowski SJ, Kowalczuk O,
Niklińska W, Chyczewski L and Kulikowski M: Mutations in the KRAS
gene in ovarian tumors. Folia Histochem Cytobiol. 47:221–224. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Della Pepa C, Tonini G, Santini D, Losito
S, Pisano C, Di Napoli M, Cecere SC, Gargiulo P and Pignata S: Low
grade serous ovarian carcinoma: From the molecular characterization
to the best therapeutic strategy. Cancer Treat Rev. 41:136–143.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Singer G, Shih Ie M, Truskinovsky A,
Umudum H and Kurman RJ: Mutational analysis of K-ras segregates
ovarian serous carcinomas into two types: Invasive MPSC (low-grade
tumor) and conventional serous carcinoma (high-grade tumor). Int J
Gynecol Pathol. 22:37–41. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Singer G, Oldt R III, Cohen Y, Wang BG,
Sidransky D, Kurman RJ and Shih IeM: Mutations in BRAF and KRAS
characterize the development of low-grade ovarian serous carcinoma.
J Natl Cancer Inst. 95:484–486. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hunter SM, Anglesio MS, Ryland GL, Sharma
R, Chiew YE, Rowley SM, Doyle MA, Li J, Gilks CB, Moss P, et al:
Molecular profiling of low grade serous ovarian tumours identifies
novel candidate driver genes. Oncotarget. 6:37663–37677. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hollis RL and Gourley C: Genetic and
molecular changes in ovarian cancer. Cancer Biol Med. 13:236–247.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ikeda K, Tate G, Suzuki T and Mitsuya T:
Effusion cytodiagnosis of carcinosarcoma derived from the female
genital tract: Immunohistochemical features of MMP-7 and Ki-67 and
immunofluorescence double staining analyses of eight cases. Gynecol
Oncol. 97:323–329. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rohlin A, Wernersson J, Engwall Y, Wiklund
L, Bjork J and Nordling M: Parallel sequencing used in detection of
mosaic mutations: Comparison with four diagnostic DNA screening
techniques. Hum Mutat. 30:1012–1020. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Salk JJ, Schmitt MW and Loeb LA: Enhancing
the accuracy of next-generation sequencing for detecting rare and
subclonal mutations. Nat Rev Genet. 19:269–285. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Micci F, Haugom L, Abeler VM, Davidson B,
Trope CG and Heim S: Genomic profile of ovarian carcinomas. BMC
cancer. 14:3152014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kim J, Park EY, Kim O, Schilder JM, Coffey
DM, Cho CH and Bast RC Jr: Cell origins of high-grade serous
ovarian cancer. Cancers (Basel). 10:4332018. View Article : Google Scholar
|
|
40
|
Lengyel E: Ovarian cancer development and
metastasis. Am J Pathol. 177:1053–1064. 2010. View Article : Google Scholar : PubMed/NCBI
|
